Language Learning

Eli Lilly’s stock soared by 8% after surpassing second-quarter earnings and revenue expectations. The firm raised its full-year revenue outlook by $3 billion, driven by strong sales of key products such as Mounjaro and Zepbound. This indicates a positive trend for the company and reflects investor confidence in its performance. Under Armour witnessed a 19%
0 Comments